RT Journal Article
SR Electronic
T1 Simulating SARS-CoV-2 epidemics by region-specific variables and modeling contact tracing app containment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.14.20101675
DO 10.1101/2020.05.14.20101675
A1 Alberto Ferrari
A1 Enrico Santus
A1 Davide Cirillo
A1 Miguel Ponce-de-Leon
A1 Nicola Marino
A1 Maria Teresa Ferretti
A1 Antonella Santuccione Chadha
A1 Nikolaos Mavridis
A1 Alfonso Valencia
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.05.14.20101675.abstract
AB Targeted contact-tracing through mobile phone apps has been proposed as an instrument to help contain the spread of COVID-19 and manage the lifting of nation-wide lockdowns currently in place in USA and Europe. However, there is an ongoing debate on its potential efficacy, especially in the light of region-specific demographics.We built an expanded SIR model of COVID-19 epidemics that accounts for region-specific population densities, and we used it to test the impact of a contact-tracing app in a number of scenarios. Using demographic and mobility data from Italy and Spain, we used the model to simulate scenarios that vary in baseline contact rates, population densities and fraction of app users in the population.Our results show that, in support of efficient isolation of symptomatic cases, app-mediated contact-tracing can successfully mitigate the epidemic even with a relatively small fraction of users, and even suppress altogether with a larger fraction of users. However, when regional differences in population density are taken into consideration, the epidemic can be significantly harder to contain in higher density areas, highlighting potential limitations of this intervention in specific contexts.This work corroborates previous results in favor of app-mediated contact-tracing as mitigation measure for COVID-19, and draws attention on the importance of region-specific demographic and mobility factors to achieve maximum efficacy in containment policies.Competing Interest StatementE.S. works for Bayer, is collaborating to COVID Safe Paths app, by MIT, and advising LEMONADE tracing app, by Nuland. A.S.C. works for Roche Pharma. M.T.F is consultant for Ely Lilly. The other authors declare no conflict of interest.Funding StatementThis material is based upon work supported by the European Commission's Horizon 2020 Program, H2020-ICT-12-2018-2020, "INFORE - Interactive Extreme-Scale Analytics and Forecasting" (ref. 825070).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Does not require IRB approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors.